Accelerated Development On The Cards In EU and US For Bluebird, Celgene’s CAR-T Therapy

 
• By Neena Brizmohun
  
T-cells attacking cancer_1200x675
Bluebird and Celgene's CAR-T therapy makes it on two key regulatory schemes
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards